Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid Arthritis Clinical Trial

Official title:

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06417398
• Other study ID #: PG-005
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: May 14, 2024
• Est. completion date: May 1, 2025

Study information

• Verified date: April 2024
• Source: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• Contact: jian wu, Doctor
• Phone: 15358805676
• Email: njwujian[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).

To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.

To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID.

To evaluate the initial efficacy of UTAA09 injection in the treatment of R/R AID subjects.

To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects.

Description:

This clinical trial was designed as a single-arm, open-label, single-center, investigator-initiated early-stage clinical study to evaluate the safety of UTAA09 injection in patients with relapsed/refractory AID. After signing the informed consent letter, qualified subjects were screened for infusion of UTAA09 injection, and their blood was collected before and after infusion for pharmacokinetics, pharmacodynamics, immunogenicity, safety and other evaluation. In addition to the baseline period, therapeutic efficacy was evaluated at a frequency of 28d, 2m, 3m, 4m, 5m, 6m, 8m, 10m, 12m after cell transfusion, and tumors were evaluated until disease progression (PD), new anti-disease therapy, death, intolerable toxicity, investigator decision, or subject's voluntary withdrawal, whichever occurred first.

All adverse events were recorded from the beginning of the subject's elutriation pre-treatment (if it occurred) until 3 months after the subject received cell transfusion or disease progression/recurrence or initiation of a new anti-disease therapy or the end of the study, whichever occurred first, and 3 months after cell transfusion or disease progression/recurrence or initiation of a new anti-disease therapy (whichever occurred first) until the end of the study. Only adverse events associated with the study product were collected

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: May 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

(2) Expected survival time =3 months; (3) Subjects with recurrent/refractory autoimmune disease who have failed standard treatment or lack effective treatment, including but not limited to systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, Sjogren's syndrome, rheumatoid arthritis, connective tissue disease-associated interstitial lung disease, immune thrombocytopenia, primary biliary cholangitis, etc.

(4) Liver and kidney function, cardiopulmonary function meet the following requirements:

• Creatinine =1.5×ULN; (2) Electrocardiogram showed no clinically significant abnormal bands;

• Blood oxygen saturation >91% in non-oxygen state;

• Total bilirubin =2×ULN; ALT and AST=2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to =3.0×ULN and the direct bilirubin =1.5×ULN.

(5) no serious mental disorders; (6) Can understand this test and have signed the informed consent.

Exclusion Criteria:

1. Malignant tumors other than R/R AID disease in the 5 years prior to screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery;

2. Hepatitis B surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal reference value range; Hepatitis C virus (HCV) Antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) Antibody positive; Syphilis positive;

3. Serious heart disease, including but not limited to unstable angina, myocardial infarction or bypass or stent surgery (within 6 months prior to screening), congestive heart failure (NYHA classification =III), and severe arrhythmia;

4. Systemic diseases that are deemed unstable by researchers: including but not limited to severe liver, kidney, or metabolic diseases that require drug treatment;

5. Active or uncontrollable infections (except mild genitourinary and upper respiratory tract infections) that require systemic treatment within 7 days prior to administration;

6. Pregnant or lactating women, and female subjects who plan pregnancy within 2 years after cell transfusion or male subjects whose partners plan pregnancy within 2 years after cell transfusion;

7. Patients who received CAR-T therapy or other gene-modified cell therapy before screening;

8. Participated in other clinical studies 1 month before screening;

9. Evidence of central nervous system invasion during subject screening;

10. Mental patients with depression or suicidal thoughts;

11. Those who received live vaccine within 28 days prior to screening;

12. Situations considered unsuitable for inclusion by other researchers.

Related Conditions & MeSH terms

• Autoimmune Diseases
• Cholangitis
• Idiopathic Inflammatory Myopathies
• Immune Thrombocytopenia
• Liver Cirrhosis, Biliary
• Lupus Erythematosus, Systemic
• Myositis
• Primary Biliary Cholangitis
• Purpura, Thrombocytopenic, Idiopathic
• Rheumatoid Arthritis
• Scleroderma, Systemic
• Sjogren's Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis
• Thrombocytopenia

Intervention

Biological:
• T cell injection targeting CD19 chimeric antigen receptor
Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AE	Type, frequency, and severity of adverse events (AEs) and laboratory abnormalities according to the Common Adverse Event Evaluation Standard NCI CTCAE version 5.0.	3 months after cell reinfusion or disease progression/recurrence or start of new anti-disease therapy (whichever occurs first)
Secondary	Peak Plasma Concentration (Cmax)	UTAA09 injection was administered in peripheral bloodCmax	3 months after cell reinfusion disease progression/recurrence or start of new anti-disease therapy (whichever occurs first)
Secondary	Area under the plasma concentration versus time curve (AUC)	UTAA09 injection was administered in peripheral blood	3 months after cell reinfusion/28d after cell reinfusion
Secondary	Content of CD19 positive cells in peripheral blood	The proportion and absolute value of CD19 positive cells in peripheral blood at each time point	every visits after infusion up to 2 years